Fulcrum Therapeutics (FULC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Fulcrum Therapeutics

NasdaqGM•Healthcare•Biotechnology

$3.85+0.01(<0.01%)Market closed

Market Cap

$287.52M

P/B

0.9x

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 31/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (4/25).

Profitability4/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 2.2x5y range 2.2x – 229.9x

Currently below its 15-quarter median.

P/B · 0.9x5y range 0.6x – 4.8x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $287.52M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-94.80M
TTM Op. Income: $-96.05M
Q. Op. Income: $-29.31M
TTM Net Income: $-85.00M
Q. Net Income: $-26.18M
EPS: $-0.34
Shares Out.: $76.26M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-94.80M and TTM operating income of $-96.05M show growth is flowing through to the bottom line. However, net income is negative at $85.00M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -2931000000.0%
Net Margin: -2617900000.0%

Op. margin of -2931000000.0% is down 949500000.0% YoY — costs are rising relative to revenue. Net margin at -2617900000.0% Over the past year, operating margin is down 48% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 0.9x

P/S of 0.0x and P/B of 0.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $323.95M
Cash: $48.47M
Long-Term Debt: N/A
Book Value: $310.70M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-16.04M
TTM Free Cash Flow: $-66.14M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-66.14M on $-16.04M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.